Biomechanical considerations for optimising subretinal injections

L’Abbate, Dario; Prescott, Kia; Geraghty, Brendan; Kearns, Victoria R.; Steel, David H.W.

doi:10.1016/j.survophthal.2024.05.004

Survey of Ophthalmology

2024

DOI: 10.1016/j.survophthal.2024.05.004

|View full text |Cite

Biomechanical considerations for optimising subretinal injections

Dario L’Abbate,

Kia Prescott,

Brendan Geraghty

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

12-month outcomes after voretigene neparvovec gene therapy in paediatric patients withRPE65-mediated inherited retinal dystrophy

Daruich,

Rateaux,

Batté

et al. 2024

Br J Ophthalmol

View full text Add to dashboard Cite

Aims To report main outcomes and complications following voretigene neparvovec (Luxturna) treatment in paediatric patients. Methods Records of patients under the age of 17 treated by subretinal administration of voretigene neparvovec for confirmed biallelicRPE65-mediated inherited retinal dystrophy were retrospectively reviewed. Best-corrected visual acuity (BCVA) and data from spectral-domain optical coherence tomography, ultra-wide-field fundus imaging and Goldmann visual field (VF) were analysed at 12 months follow-up. Results 12 eyes of six patients (mean age: 7.8 years) were analysed. No intraoperative complications occurred. BCVA significantly improved at 12-month follow-up (mean LogMAR (logarithm of the minimal angle of resolution) BCVA: 1.0±0.8 at baseline vs 0.6±0.3 at 12 months, p=0.001). Mean central macular thickness and central outer nuclear layer thickness did not change at 12 months follow-up. VF V4e isopter did not show significant changes. Postoperatively complications included: elevated intraocular pressure in two eyes of the same patient, a parafoveal lamellar hole at 3 months post-treatment and atrophy on the injection site observed in all eyes except one, which significantly enlarged during 12 months (p=0.008). Conclusions Most paediatric patients treated by voretigene neparvovec showed a significant increase in visual function at 12 months follow-up. None of the postoperative complications prevented gains in visual function.

show abstract

12-month outcomes after voretigene neparvovec gene therapy in paediatric patients withRPE65-mediated inherited retinal dystrophy

Daruich,

Rateaux,

Batté

et al. 2024

Br J Ophthalmol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Biomechanical considerations for optimising subretinal injections

Cited by 1 publication

References 93 publications

12-month outcomes after voretigene neparvovec gene therapy in paediatric patients withRPE65-mediated inherited retinal dystrophy

12-month outcomes after voretigene neparvovec gene therapy in paediatric patients withRPE65-mediated inherited retinal dystrophy

Contact Info

Product

Resources

About